KCTD13

Across TCGA pan-cancer cohorts, KCTD13 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated KCTD13 data layer compared with 22 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher KCTD13 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated KCTD13 expression acts as an unfavorable survival marker.

LSCC and GBM are the cancer types where KCTD13 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	All	0.360	1.000	.018	7	view →
GBM	OS	Tertile	All	0.370	0.680	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

KCTD13–LSCC (DFS)

Open the LSCC breakdown →